InterVene is a technology company.
InterVene has raised $13.0M across 1 funding round.
InterVene has raised $13.0M in total across 1 funding round.
InterVene has raised $13.0M in total across 1 funding round.
InterVene's investors include RiverVest.
InterVene, Inc. is a clinical-stage medical device company developing innovative catheter-based technologies to treat chronic venous insufficiency (CVI) and related complications like venous in-stent restenosis (ISR) and deep vein obstructions. Its flagship products include the Recana™ Thrombectomy Catheter System, which mechanically removes thrombotic obstructions in veins and stents, and the BlueLeaf® Endovenous Valve Formation System, a non-implant solution for deep vein reflux.[1][2][3][4][6] InterVene serves interventional physicians and patients with severe venous disease, addressing unmet needs where current therapies fall short, such as persistent blockages post-stenting or valve failure causing lifelong symptoms like pain, swelling, and ulcers.[1][2][6] The company, based in Redwood City, California, has shown growth through first-in-human procedures, FDA Breakthrough Device Designation for BlueLeaf, and $15 million in Series B funding from investors like RiverVest Venture Partners and Treo Ventures.[3][4]
InterVene emerged from the Stanford Biodesign Fellowship program and served as a Company-In-Residence at the Fogarty Institute for Innovation, leveraging expertise in interventional cardiology to tackle deep venous challenges.[4][6] Founded by Fletcher Wilson, who serves as CEO, the company was formed by a team of experienced professionals in peripheral vasculature, cardiovascular, and neurovascular markets, advised by leading venous physicians.[4][5][6] The idea stemmed from gaps in CVI treatments—particularly deep vein reflux and obstructions—where options were limited to compression therapy or surgery; early pivotal moments included a multi-center feasibility study in New Zealand and Australia treating 10 patients with the BlueLeaf system, yielding positive physician feedback and enabling Series B fundraising.[6] This traction supported U.S. trial planning with the FDA and presentations at conferences like Transcatheter Cardiovascular Therapeutics.[6]
InterVene rides the venous interventional wave, fueled by rising CVI prevalence—affecting millions in the U.S. at billions in annual costs—and strategic moves by giants like Boston Scientific and Medtronic into venous stenting and therapies.[6] Timing aligns with demand for minimally invasive, durable solutions amid aging populations and post-thrombotic cases; market forces favor catheter-based innovations over surgery, especially for deep veins where compression alone fails.[1][6] By pioneering non-implant valve formation and advanced thrombectomy, InterVene influences the ecosystem, accelerating trials via partnerships like University Hospital Galway and setting benchmarks for B2B hospital adoption in endovascular care.[3][6]
InterVene's near-term path involves U.S. pivotal trials for Recana and BlueLeaf, potential CE Mark pursuits post-first-in-human success, and commercialization leveraging FDA Breakthrough status to speed approvals.[3][6] Trends like expanding venous markets, AI-enhanced imaging for procedures, and value-based care will amplify demand for its cost-saving, patient-centric devices. As a leader in underserved deep venous niches, InterVene could evolve into an acquisition target or platform expander, transforming CVI management from symptom relief to curative interventions—ultimately delivering life-changing options where none existed.[1][2][5]
InterVene has raised $13.0M across 1 funding round. Most recently, it raised $13.0M Series A in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $13.0M Series A | RiverVest |